NEW ANTIBACTERIAL COMPOUNDS

• US 20200095225A9
• Filed: 06/05/2017
• Published: 03/26/2020
• Est. Priority Date: 06/08/2016
• Status: Active Grant

• Current Assignee: Aziende Chimiche Riunite Angelini Francesco Acraf SPA (Angelini Finanziaria SPA)
• Original Assignee: Aziende Chimiche Riunite Angelini Francesco Acraf SPA (Angelini Finanziaria SPA)
• Inventors: OMBRATO, Rosella, MAGARO, Gabriele, GAROFALO, Barbara, FURLOTTI, Guido, MANGANO, Giorgina, CAPEZZONE DE JOANNON, Alessandra
• Granted Patent: US 10,640,488 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/16 Peri-condensed systems
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: C07D 491/052 the oxygen-containing ring being six-membered
• CPC Class Codes: C07D 493/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/04 Ortho-condensed systems
• CPC Class Codes: C07D 513/04 Ortho-condensed systems
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

Claims

1. :

A compound of formula (1);

A-L₁-Y-L₂-R—

B 

 

(1)

wherein

A is a cyclic group having the formula (II);

2. :

The compound according to claim 1, wherein R₂ is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, and a bromine atom.

3. :

The compound according to claim 1, wherein R₂ is selected from the group consisting of a hydrogen atom and a fluorine atom.

4. :

The compound according to claim 1, wherein L₁ is a σ

bond or a methylene group (—

CH₂—

).

5. :

The compound according to claim 1, wherein L₂ is a σ

bond, a (C_1-3)alkylenyl group, NR′

″

group, —

NR′

″

—

(C_1-3)alkylenyl group, (C_1-3)alkylenyl-NR′

″

—

group, —

NR′

″

—

(C_1-3)alkylenyl-NR′

″

—

group, or (C_1-3)alkylenyl-NR′

″

—

(C_1-3)alkylenyl group, said group being optionally substituted with one or more hydroxy group.

6. :

The compound according to claim 5, wherein L₂ is a σ

bond, a (C_1-2)alkylenyl group, NR′

″

group, —

NR′

″

—

(C_1-2)alkylenyl group, (C_1-2)alkylenyl-NR′

″

—

group, —

NR′

″

—

(C_1-2)alkylenyl-NR′

″

—

group, or (C_1-2)alkylenyl-NR′

″

—

(C_1-2)alkylenyl group, said group being optionally substituted with one hydroxy group.

7. :

The compound according to claim 1, wherein R is a σ

bond or an aromatic heterocyclic ring having 5 members containing one or more nitrogen atoms, optionally substituted with CH₂CN or CN.

8. :

The compound according to claim 7, wherein R is a 6 bond, a 1H-imidazol-4-yl group, or a 1H-pyrrol-2-yl group, optionally substituted with CH₂CN or CN

9. :

The compound according to claim 1, wherein A is a cyclic group having one of the following formulae;

10. :

The compound according to claim 1, wherein Y is a ring having one of the following formulae;

11. :

The compound according to claim 1, wherein B is a cyclic group having one of the following formulae;

12. :

A pharmaceutical composition, comprising at least one compound, salt thereof with a pharmaceutically acceptable organic or inorganic acid or with a pharmaceutically acceptable organic or inorganic base, enantiomer, quaternary ammonium salt thereof, or N-oxide thereof according to claim 1, and

at least one inert pharmaceutically acceptable excipient.

13. :

The compound according to claim 1, for use in medicine.

14. :

The compound according to claim 1, for use in the treatment of a bacterial infection.

15. :

The compound according to claim 14, wherein said bacterial infection is selected from the group consisting of a skin infection, a mucosal infection, a gynecological infection, a respiratory tract infection (RTI), a CNS infections, a gastro-intestinal infection, a bone infection, a cardiovascular infection, a sexually transmitted infection, and a urinary tract infection.

16. :

A method for treating a bacterial infection, comprising administering an effective amount of a compound, salt thereof with a pharmaceutically acceptable organic or inorganic acid or with a pharmaceutically acceptable organic or inorganic base, enantiomer, quaternary ammonium salt thereof, or N-oxide thereof according to claim 1 to a patient in need thereof.

17. :

The method according to claim 16, wherein said bacterial infection is selected from the group consisting of a skin infection, a mucosal infection, a gynecological infection, a respiratory tract infection (RTI), a CNS infections, a gastro-intestinal infection, a bone infection, a cardiovascular infection, a sexually transmitted infection, and a urinary tract infection.